The Latest Breaking News from BofA

When loyalty is rewarded: Top earners who stay in their jobs get much larger pay increases than those who switch

The benefits of job hopping may be slowing down, but it still can pay off for younger workers.

Fortune · May 30

Blockbuster Earnings Just Sent DELL Stock Soaring. What Comes Next.

Dell stock soars on blockbuster Q1 earnings and impressive future guidance. BofA raises price target on DELL shares to $500.

Barchart · May 29

Listed new-age internet firms brace for a costly ride as war clouds math

The March quarter was largely stable for companies, with most firms reporting revenue growth in line with expectations and improving operating metrics. However, food delivery, quick commerce, ecommerce, beauty, eyewear, furniture and logistics firms are preparing for higher costs in the upcoming quarters even as consumer sentiment remains uneven.

The Economic Times · May 29

Dear Google Stock Fans, Mark Your Calendars for May 19

Alphabet’s Google I/O event is expected to showcase major Gemini AI upgrades and deeper agentic AI integration.

Barchart · May 19

Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference

Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and colorectal cancers during a Bank of America biotech conference session. Jonathan Lim, Erasca’s chair

MarketBeat · May 16

Robust Earnings Growth and Innovation Will Help the Marvell Stock Uptrend Keep Going

AMD has disclosed a stake in Marvell Technologies

Barchart · May 15

This Analyst Just Upgraded Akamai Technologies. Here's Why.

Akamai stock rallies as Bank of America raises its price target to $175. Here’s why BofA is constructive on AKAM shares for the remainder of 2026.

Barchart · May 14

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An

MarketBeat · May 14

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conferenc

MarketBeat · May 14

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three potential near-term product launches from the company’s late-stage pipeline. Tom Trimarchi, BridgeBi

MarketBeat · May 13